Pharmacological Analysis of Human Samples Collected in Clinical Trials Performed Outside of the Intramural National Cancer Institute
Various human samples (e.g., serum, plasma, whole blood, erythrocytes, urine, feces, bile,
and/or saliva) will be collected from cancer patients enrolled on approved clinical trials,
in accordance with the local protocol. These trials are being conducted at outside
institutions, in collaboration with the National Cancer Institute (NCI) and the samples will
be sent to the NCI for pharmacological analysis, involving determination of parent drug
and/or metabolite concentrations and subsequent pharmacokinetics and statistical data
analysis. This study aims to further characterize the clinical pharmacokinetic behavior of
select cancer therapeutics. Future collaborators will be added via the protocol amendment
procedure.
Observational
N/A
William D Figg, Pharm.D.
Principal Investigator
National Cancer Institute (NCI)
United States: Federal Government
999903242
NCT00339664
June 2003
Name | Location |
---|---|
Hollings Cancer Center at Medical University of South Carolina | Charleston, South Carolina 29425 |
Case Western Reserve University | Cleveland, Ohio 44106 |
H. Lee Moffitt Cancer Center & Research Institute | Tampa, Florida 33612 |
University of Chicago | Chicago, Illinois 60637 |
Johns Hopkins Medical Center | Baltimore, Maryland |
Sidney Kimmel Comprehensive Cancer Center | Lutherville, Maryland |
Mayo Clinic, Rochester | Rochester, Minnesota 55905 |
University of Maryland, Baltimore | Baltimore, Maryland 21201-1595 |
University of Maryland at Amish Research Clinic, Lancaster | Lancaster, Pennsylvania |
Abramson Cancer Center, University of Pennsylvania | Philadelphia, Pennsylvania 19104 |
Hillman Cancer Center at University of Pittsburg Cancer Institute | Pittsburg, Pennsylvania 15261 |
Massey Cancer Center, Virginia Commonwealth University | Richmond, Virginia 23298 |
McGuire Veterans Administration Medical Center | Richmond, Virginia 23249 |